10 April - 12 April 2024
40th SCI Process Development Symposium
Organised by:
SCI's Fine Chemicals Group
Churchill College, Cambridge, UK
Registration Closed
This event is currently unavailable for registration.
Share this event
Synopsis
Process Development is the application of chemistry to the scale up of new synthetic processes from the laboratory, through pilot plant to full scale commercial manufacture and into life cycle management. It is an extremely broad discipline, crossing the boundaries between synthetic organic chemistry, process technology and chemical engineering.
The area of Process Development continues to be a challenging and important area for the research into and application of modern synthetic organic chemistry, as well as enabling technologies.
Attendees
The symposium aims to bring together a wide range of speakers from across the Pharmaceutical, Agrochemical and Fine Chemical industries, as well as from an academic background. This meeting brings together experts from across the entire spectrum of the discipline to present state of the art process development.Sponsorship and Exhibition
For further information and prices, please email conferences@soci.org.
Accommodation
En-suite accommodation can be booked for delegates at the college. Bedrooms will be allocated on a first come, first served basis. The accommodation package is for 2 nights – Wednesday 10 and Thursday 11 April and includes full English or Continental breakfast plus an evening meal on Wednesday 10 April. Rooms must be vacated by 10.00am on the day of departure. Luggage storage will be made available on the day of departure.Please note: Bedrooms at the college will be available from 14:00 on the day of arrival.
Those not wishing to stay in college accommodation can book accommodation directly through www.visitcambridge.org
Programme
Wednesday 10 April
- 11.00
- Registration and refreshments
- 12.15
- Lunch and exhibition
CHAIRPERSON: David Lathbury, Astute chemical development consulting Ltd, UK
- 13.25
- Opening remarks
- 13.30
- The largest small molecule: How chemistry enabled the discovery and development of PCSK9 inhibitor MK-0616
Dr David Thaisrivongs, MSD, USA - 14.10
- A reluctant process chemist – A review of key projects in a 35-year career
Dr Ian Lennon, Chiralquest, UK - 14.50
- From early phase to full scale manufacturing. An overview of biocatalysis at Novartis pharma
Thierry Schlama, Novartis Basel, Switzerland - 15.30
- Refreshment break and exhibition
CHAIRPERSON: Max Espensen, Pharmaron, UK
- 16.10
- Adventures in the development of complex pharmaceuticals
Dr Francisco Gonzalez Bobes, Bristol-Myers Squibb, USA - 16.50
- Development of a large-scale photoredox fluorodecarboxylation of aliphatic carboxylic acids
Dr Aaron Dumas, Pharmaron Hoddesdon, UK - 17.20
- Closing remarks
- 17.30
- Wine reception sponsored by ChiralQuest (until 18.15)
- 19.00
- Dinner for residents of the college
Thursday 11 April
CHAIRPERSON: Hilmar Weinmann, Johnson & Johnson Innovative Medicine, Belgium
- 09:00
- Minimizing hazards and risks in chemical process development: Structure-related reactivity investigation of five-membered cyclic sulfamidates
Dr Michael Parmentier, Novartis, Switzerland - 09.40
- The impact of bringing development capabilities into discovery phase in finding long-acting RSV PreP inhibitors
Kiran Matcha, Johnson & Johnson Innovative Medicine, Belgium - 10.20
- Refreshment break and exhibition
CHAIRPERSON: Robert Walton, Pfizer, UK
- 10.50
- Case study
Chloe Markham, GlaxoSmithKliine, UK - 11.30
- Nitrosamines, the journey so far
Dr Gair Ford, AstraZeneca, UK - 12.10
- Lunch and exhibition
- 13.10
- Resolution of racemates: From classical to contemporary
Dr Michel Leeman, Symeres, The Netherlands - 13.50
- Unexpected axial chirality behaviour: Thinking outside the box for the improvement of Lartesertib synthesis
Nunzia Langella, Merck, Italy - 14.30
- Data-driven chemistry
Prof Jonathan M. Goodman, University of Cambridge - 15.10
- Refreshment break and exhibition
CHAIRPERSON: Matt Burns, AstraZeneca, UK
- 15.40
- Approaches to nitrosamines risk assessments and control strategies
Paula Tomlin, AstraZeneca, UK - 16.20
- Process chemistry award winner 2023
Winner to be announced in December 2023 - 17.20
- Closing remarks
- 17.30
- Wine reception (until 18.15)
- 19.00
- Symposium dinner
Friday 12 April
CHAIRPERSON: Hazmi Tajuddin, Syngenta, UK
- 09.00
- Rapid scale-up of a novel photochemical C–N oxidative coupling: capability development and pilot-plant implementation
Alan Robinson, Syngenta, Switzerland - 09.40
- Case study
James Clarke, Pfizer, UK - 10.20
- Refreshment break and exhibition
CHAIRPERSON: Richard Horan, GlaxoSmithKline, UK
- 10.50
- Conquering the challenging manufacture and analysis of lipidic palmitoyl ethanolamine prodrug ETX-018810
David Witty, Eliem and Jade Owen, Veranova - 11.30
- Development of a scalable, sustainable, and economical route to balcinrenone
Dr Zeina Neouchy, AstraZeneca, UK - 12.10
- Close
SCI’s Fine Chemicals Group are committed to promoting diversity and equality in the chemical sciences. We aim to identify high quality speakers for all our conferences with full inclusivity where attendees from all backgrounds are welcome. We are open to offering flexible presentation options.
Venue and Contact
Churchill College
Storey's Way
Cambridge
CB3 0DS
Conference Team
Tel: +44 (0)20 7598 1561
Email: conferences@soci.org
Fees
|
Early bird- ends 29 January 2024 |
|
After early bird |
Become an SCI Member and save on this and future events
See Membership OptionsSign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
Booking Process/Deadlines
CPD Info
SCI Members attending this meeting are able to claim CPD points.
Sponsors
Gold Exhibitors
Silver Exhibitors
-
Almac
-
Pharmaron
Bronze Exhibitors
-
Key Organics
-
ABCR UK
-
Radleys
-
Asymchem
-
Stolichem
-
ChiralQuest
Organising committee
-
Max Espensen, SCI/Pharmaron
-
Richard Horan, SCI/GlaxoSmithKline
-
Dave Lathbury, SCI/Astute Chemical Development Ltd
-
Hazmi Tajuddin, Syngenta
-
Robert Walton, SCI/Pfizer
-
Hilmar Weinmann, Johnson & Johnson Innovative Medicine
-
Matt Burns, SCI/AstraZeneca